Mirum Pharmaceuticals 8th Annual Wolfe Research Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Welcome to day two of the Wolfe Research Healthcare Conference. I'm Kalpit Patel. I'm pleased to have here with me the team from Mirum, Andrew and Eric. Welcome, and thank you for joining us. Eric, it's been a pretty eventful few months for Mirum in recent times. You've had some positive clinical readouts, launched another commercial medicine, and raised revenue guidance again. Maybe to kick us off, what should we look out over the next 12-18 months, and what do you think investors are still underappreciating about where the business is heading?
Thank you, Kalpit, and first of all, thank you to Wolfe Research for hosting us, and let me remind you that we will be making forward-looking statements, so please look at the risk factors in our regulatory filings. I think it's often investors like to focus down on the details as they should, and really on the news of the day and maybe comparing to other programs, et cetera. When you do that, it's often easy to lose view of the overall picture. So let me remind you that less than 5% of orphan diseases have an FDA-approved medicine, and we are trying to change that by bringing to market medicines that have a profound positive impact on patients' lives. To date, we have four approved medicines with many more to come.
Based on all the successes in the clinic we've seen this year, we expect five sNDA, NDA, and BLA filings next year. So within 18 months, we should have many more medicines approved and indications approved. With that, we expect very significant revenue growth over the next 5+ years, resulting in very significant cash flow generation. I think when you focus too much on the details, you lose track of the overall picture and where we are headed.
Got it. Okay, and I want to start with LIVMARLI first, which continues to drive a lot of commercial momentum. You reported about $133 million in third-quarter sales, and you've talked about sustaining that to $10 million-$15 million roughly in sequential quarterly growth over the next year. How much of that is coming from newly diagnosed adult PFIC patients versus deeper penetration of the existing population, or just weight-based dose increases that you would expect as you go into the adult PFIC population?
Yeah, thank you. They are all elements. Alagille is growing steadily quarter-over-quarter. We keep adding new patients. We keep anchoring on being about 50% penetrated of the treatment-eligible population. Clearly, the big grower is PFIC, where we think it is early days still. We are adding a lot of patients. They are dosed twice a day compared to Alagille, which is daily dosing, and they tend to be older and therefore heavier and consume more drugs. So that clearly drives the revenue growth, and we think we have a long way to go, which is why we came out with this expectation that our sequential increases of $10 million-$15 million should continue for the foreseeable future.
Okay. What are you learning about how quickly these patients can be found or diagnosed and brought onto therapy?
Yeah, I think genetic testing is very common amongst pediatric hepatologists, but much less so amongst adult hepatologists and GI docs. We are out there trying to educate that community on the importance of genetic testing, and that leads to a number of these patients being found. So, it is work, but it is work we are doing, and it is very successful. We are also not the only ones doing it, right? We do have a competitor, and I think in PFIC, we are probably splitting the opportunity more or less. Between the two of us, I think we are making a lot of progress, and that is resulting in newly diagnosed patients found every month.
Okay. You also had separately a successful EXPAND study recently. We saw a benefit in the biliary atresia patients in that study. Previously, you mentioned that about 2,000 BA patients are there in the U.S. and across Europe. Are these patients already concentrated in the centers that you are calling on, and how straightforward is this expansion, or do you need to go out and find these patients, expand the sales force?
Good question. There is a very high level of overlap with our pediatric hepatologists, and that's because these patients, the biliary atresia patients, all get the Kasai procedure very early in life, so they're already identified. In total, we think with about 1,000 in the U.S., that would mean it's about the same number of patients as for Alagille syndrome. But the dosing is higher, and there shouldn't be any competition here. We think the opportunity is at least an Alagille syndrome.
Got it. Should we assume that the trajectory is a little faster than what we had seen with Alagille and PFIC historically?
I mean, you would think so based on what I've said, but we'll see.
Okay. Maybe Andrew, moving on to PSC. You clearly had a positive trial there, and one of the biggest questions that we get is the uncertainty on the regulatory path for PSC. The FDA had recommended another phase III despite your original trial hitting stat sig. Can you help us understand if anything has changed since your public announcement that the FDA is requiring or asking for another phase III? You presented some data at AASLD this past weekend. Anything from those subgroup analysis that should help drive confidence for this resubmission?
Yeah. It's funny, we get that question a lot too. But effectively, there's no material update to provide. Our conversations are progressing. Everything's on plan for a submission in the first half of next year. If something does come out of this interaction that is material or materially changes what we are planning on doing, then we'll tell you. But so far, so good. The IBD analysis, it's important to note that that was not in reaction to a question from the FDA recently. This was all part of the original design and plan. Back in 2019, this was an area of focus for us and the FDA just to make sure that this is safe in patients with IBD since the majority of PSC patients have that. The analysis that we presented at AASLD shows that. So there's really no exacerbation.
We did everything we could to assess that in the study, and I think it's a pretty reassuring analysis.
How directly do those analysis support what the FDA is asking for?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
